The last 10 years have witnessed transformative advances in cancer treatment, with immune ICIs targeting PD‐1/PD‐L1 and CTLA‐4 pathways demonstrating unprecedented clinical efficacy across multiple malignancies [166, 289]. This evidence concerns the gene CD274 and cancer.